A remarkable advance in the neuropharmacological properties of Asteraceae has been provided by Viola et al. and Avallone et al. (55,56). They made the important observation that apigenin blocks the binding of flunitrazepam to GABAA receptors, displaces flumazenil from the central benzodiazepine binding site, and reduces GABA-activated chloride channels. Apigenin, or 5,7,4'-trihydroxyflavone, is widespread in members of the Asteraceae family and is notably present in Matricaria chamomilla L. (Chamomilla recutita [L.] Rauschert) or German chamomile (matricaria, British Pharmaceutical Codex, 1949).
Was this article helpful?